All In Biotech

Drug Trial Radar · NCT05755386

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune-complex-mediated Membranoproliferative Glomerulonephritis (IC-MPGN)

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

106

Planned (sponsor's estimate)

Start

Oct 2, 2023

Primary completion

Oct 27, 2028

Study completion May 31, 2029

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.

Conditions

  • IC-MPGN

Interventions

  • PlaceboDrug

    Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

  • iptacopanDrug

    iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Log-transformed ratio to baseline in UPCR (sampled from a 24-hour urine collection) at 6 months.Time frame: 6 months (double-blind)
  2. Log-transformed ratio to baseline in UPCR at the 18-month visit (each study treatment arm)Time frame: 18 months
  3. Log-transformed ratio to 12-month visit in UPCR at the 18-month visit in the placebo arm.Time frame: 18 months

Locations

131 sites in 23 countries. Site status is shown where the registry gives one.

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California · Recruiting

  • Univ Cali Irvine ALS Neuromuscular

    Orange, California · Recruiting

  • UCSF

    San Francisco, California · Recruiting

  • Olive View UCLA Medical Center

    Sylmar, California · Recruiting

  • Childrens Hospital Colorado

    Aurora, Colorado · Recruiting

  • Nicklaus Childrens Hospital

    Miami, Florida · Recruiting

  • Emory University School of Medicine-Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Boston Univ School of Medicine

    Boston, Massachusetts · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Washington University in St Louis

    St Louis, Missouri · Recruiting

  • University of New Mexico

    Albuquerque, New Mexico · Recruiting

  • Col Uni Med Center New York Presby

    New York, New York · Recruiting

  • University Of Cincinnati

    Cincinnati, Ohio · Recruiting

  • OHSU Dept of Nephrology

    Portland, Oregon · Recruiting

  • Univ of Pennsylvania Medical Center

    Philadelphia, Pennsylvania · Recruiting

  • MUSC Health Lancaster Med Ctr

    Lancaster, South Carolina · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Prolato Clinical Research Center

    Houston, Texas · Recruiting

  • Baylor Scott and White Research

    Temple, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

  • Novartis Investigative Site

    Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Argentina · Recruiting

  • Novartis Investigative Site

    Santa Fe, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina · Recruiting

  • Novartis Investigative Site

    Salvador, Brazil · Recruiting

  • Novartis Investigative Site

    Fortaleza, Ceará, Brazil · Recruiting

  • Novartis Investigative Site

    Brasília, Federal District, Brazil · Withdrawn

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Novartis Investigative Site

    Recife, Pernambuco, Brazil · Recruiting

  • Novartis Investigative Site

    Niterói, Rio de Janeiro, Brazil · Withdrawn

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil · Withdrawn

  • Novartis Investigative Site

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Novartis Investigative Site

    Botucatu, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Santo André, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Sao Jose Rio Preto, São Paulo, Brazil · Recruiting

Showing 40 of 131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.